Abdul Rafeh Naqash, MD
Hematology & Oncology · Oklahoma City, OKNPI 1528499712
Payments from drug & device makers
Across 499 payments — averaging $2270.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$291K
- ADC Therapeutics America, Inc.$273K
- Merck$210K
- Coherus Oncology, Inc.$118K
- Exelixis Inc.$58K
- Pfizer$48K
- plus $135K from 21 others
Across 1 payment — averaging $443.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$443
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 3 | $291,369 |
| ADC Therapeutics America, Inc. | 285 | $272,795 |
| Merck | 7 | $210,416 |
| Coherus Oncology, Inc. | 88 | $117,546 |
| Exelixis Inc. | 25 | $58,472 |
| Pfizer | 23 | $48,041 |
| Regeneron | 16 | $43,550 |
| Immunocore Limited | 8 | $26,089 |
| Genentech, Inc. | 1 | $21,000 |
| AbbVie | 9 | $15,990 |
| Jazz Pharmaceuticals Inc. | 6 | $11,540 |
| Foundation Medicine, Inc. | 1 | $7,353 |
| EMD Serono Research & Development Institute, Inc. | 1 | $5,034 |
| Regeneron Healthcare Solutions, Inc. | 5 | $3,198 |
| AstraZeneca | 2 | $234 |
| GE HealthCare | 2 | $204 |
| Daiichi Sankyo Inc. | 4 | $98 |
| Sanofi | 2 | $48 |
| Bristol Myers Squibb | 2 | $43 |
| Lilly USA, LLC | 2 | $28 |
| Recordati_rare_diseases_inc. | 1 | $26 |
| Johnson & Johnson | 1 | $25 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| BTG International Inc. | 1 | $15 |
| Karyopharm Therapeutics Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $11 |
How this compares
$1,133,164 in reported general payments places this provider in the 95th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Oklahoma City
- Adam AschOklahoma City$2M
- Adanma Anji Ayanambakkam AttanathiOklahoma City$1.9M
- Hassan HatoumOklahoma City$1.4M
- Sami IbrahimiOklahoma City$1M
- Carrie YuenOklahoma City$564K
- David LamOklahoma City$445K
- Romeo MandanasOklahoma City$419K
- Carla KurkjianOklahoma City$310K
- Sonia VargheseOklahoma City$295K
- Mohammad RazaqOklahoma City$267K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.